Splenomegaly, hypersplenism and coagulation abnormalities in liver disease

Best Practice and Research: Clinical Gastroenterology

Volumn 14, Issue 6, 2000, Pages 1009-1031

  McCormick, P Aiden ^a   Murphy, Karen M ^a  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

Cirrhosis; Hypersplenism; Portal hypertension; Spleen; Splenomegaly; Thrombocytopenia

Indexed keywords

ANTIFIBRINOLYTIC AGENT; APROTININ; BLOOD CLOTTING FACTOR; CYTOKINE; DESMOPRESSIN; FRESH FROZEN PLASMA; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH FACTOR; HEPARIN; PLACEBO; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT ERYTHROPOIETIN; TERLIPRESSIN; THROMBOPOIETIN; TRANEXAMIC ACID; VON WILLEBRAND FACTOR;

ANEURYSM; ANEURYSM RUPTURE; ARTICLE; ARTIFICIAL EMBOLISM; BLEEDING; BLOOD CLOTTING DISORDER; CLINICAL ARTICLE; CRYOPRECIPITATE; DISSEMINATED INTRAVASCULAR CLOTTING; HEPATIC VEIN; HEREDITY; HUMAN; HYPERSPLENISM; LIVER DISEASE; LIVER TRANSPLANTATION; NONHUMAN; PORTAL HYPERTENSION; PORTAL VEIN; PORTOSYSTEMIC ANASTOMOSIS; PROTEIN SYNTHESIS; RAT; SPLEEN ARTERY; SPLENECTOMY; SPLENOMEGALY; SYMPTOM; THROMBOCYTOPENIA; THROMBOSIS;

EID: 0034500502     PISSN: 15216918     EISSN: None     Source Type: Journal    
DOI: 10.1053/bega.2000.0144     Document Type: Article

References (100)

1. Myelofibrosis with myeloid metaplasia
2. Effect of portal hypertension on hypersplenism
3. Splenomegaly at a university hospital compared to a nearby county hospital in 317 patients
4. Apropos de la communication de M Vaquez
5. Splenectomy is contraindicated for thrombocytopenia secondary to portal hypertension
6. Measurement of spleen size and its relation to hypersplenism and portal haemodynamics in portal hypertension due to hepatic cirrhosis
7. Haematological abnormalities in liver disease
8. Abnormal phospholipid metabolism in spur cell anaemia: Decreased fatty acid incorporation into phosphatidylethanolamine and increased incorporation into acylcarnitine in spur cell anaemia erythrocytes
9. Reduced serum levels of immunoreactive erythropoietin in patients with cirrhosis and chronic anaemia
10. Autologous blood transfusion for hepatectomy in patients with cirrhosis and hepatocellular carcinoma: Use of recombinant human erythropoietin
11. Changes in platelet kinetics after a partial splenic artery embolization in cirrhotic patients with hypersplenism
12. Organ distribution and fate of human platelets: Studies of asplenic and splenomegalic patients
13. Inter-relationships between platelet count, platelet IgG, serum IgG, immune complexes and severity of liver disease
14. Translocation of platelets into Disse spaces and their entry into hepatocytes in response to lipopolysaccharides, interleukin-i and tumour necrosis factor: The role of kupffer cells
15. Platelets accumulation in the liver after partial hepatectomy: The role of platelets in liver regeneration
16. Functional, life-threatening disorders and splenectomy following liver transplantation
17. Surgical anatomy of the human spleen
18. Late postoperative follow-up of patients submitted to subtotal splenectomy
19. Partial splenic embolization in the treatment of thrombocytopenia after liver transplantation
20. Partial splenic embolization in five children with hypersplenism: Effects of reduced-volume embolization on efficacy and morbidity
21. Effect of transjugular intrahepatic portosystemic shunt on secondary hypersplenism
22. The haematologic consequences of transjugular intrahepatic portosystemic shunts
23. Thrombocytopenia in liver transplant recipients
24. Does auxiliary heterotropic liver transplantation reverse hypersplenism and portal hypertension?
25. Short and long-term changes in splanchnic haemodynamics after liver transplantation (OLT)
26. Splenic irradiation for symptomatic splenomegaly associated with myelofibrosis with myeloid metaplasia
27. Congestive hypersplenism: Treatment by means of radioembolization of the spleen with Y-90
28. Effect of recombinant human erythropoietin treatment on circulating reticulated platelets in uraemic patient: Association with early improvement in platelet function
29. Thrombocytopenia of chronic liver disease corrected by erythropoietin treatment
30. Thrombopoietin
31. Changes in serum thrombopoietin levels after splenectomy
32. Thrombopoietin concentrations are low in patients with cirrhosis and thrombocytopenia and are restored after orthotopic liver transplantation
33. Blunted thrombopoietin response to interferon alfa-induced thrombocytopenia during treatment for hepatitis C
34. Haematological abnormalities in early abstinent alcoholics are closely associated with alterations in thrombopoietin and erythropoietin profiles
35. Coagulopathies of liver disease
36. Haemostatic problems in liver disease
37. Platelet abnormalities in hepatobiliary disease
38. The control of production and release of haemostatic factors in the endothelial cell
39. Production and availability of thromboplastin in endothelial cells: The effect of thrombin, endotoxin and platelets
40. The tissue factor pathway: How it has become a 'prima ballerina'
41. Structure and function of protein C
42. Protein C and S deficiency
43. Synthesis of coagulation factors by a clonal strain of rat hepatoma cells
44. Distribution of factor VIII mRNA and antigen in human liver and other tissues
45. Observations of increased levels of blood coagulation factors and plasma proteins in cholestatic liver disease
46. Vitamin K: Biochemistry, function and deficiency
47. Vitamin K metabolism and nutrition
48. Acquired vitamin K dependent carboxylation in liver disease
49. Acquired dysfibrinogenaemia in liver disease
50. Thromboelastography
51. Haemostasis in liver transplantation
52. Intra-operative changes in blood coagulation and thromboelastographic monitoring in liver transplantation
53. The aggregation of human platelets by ascitic fluid: A possible mechanism for disseminated intravascular coagulation complicating LeVeen shunts
54. Disseminated intravascular coagulation in liver cirrhosis: Fact or fiction?
55. Fibrinopeptide a in liver cirrhosis: Evidence against a major contribution of disseminated intravascular coagulation to coagulopathy of chronic liver disease
56. Analysis of elevated fibrin(ogen) degradation product levels in patients with liver disease
57. AICF and DIC in liver cirrhosis: Expressions of a hypercoagulable state
58. High D-dimer levels: A possible index of risk of overt bleeding and/or digestive bleeding in advanced liver cirrhosis
59. The influence of antithrombin III (ATIII) substitution to super-normal activities on systemic procoagulant turnover in patients with end stage chronic liver disease
60. Clinical use of antithrombin concentrates
61. Recombinant activated factor VII as a universal haemostatic agent
62. Correction of both prothrombin time and primary haemostasis by recombinant factor VII during therapeutic alcohol injection of hepatocellular cancer in liver cirrhosis
63. Quick correction of haemostasis in two patients with fulminant liver failure undergoing liver transplantation by recombinant activated factor VII
64. Randomized controlled trial of desmopressin plus terlipressin vs terlipressin alone for the treatment of acute variceal hemorrhage in cirrhotic patients: A multicenter, double-blind study
65. Hemostatic drugs
66. The prophylactic effect of aprotinin on intraoperative bleeding in liver transplantation: A randomized clinical study
67. Aprotinin and transfusion requirements in orthotopic liver transplantation: A multicentre randomised double-blind study
68. Venous thrombosis: A multicausal disease
69. Portal thrombosis in cirrhotics, a retrospective analysis
70. Inherited coagulation disorders in cirrhotic patients with portal vein thrombosis
71. Cause of portal or hepatic venous thrombosis in adults: The role of multiple concurrent factors
72. Etiology of portal vein thrombosis in adults. A prospective evaluation of primary myeloproliferative disorders
73. In vitro colony culture and chromosomal studies in hepatic and portal vein thrombosis-possible evidence of an occult myeloproliferative disorder
74. Hepatic and portal vein thrombosis associated with chronic myeloproliferative disorders
75. Spontaneous erythroid colony formation as the clue to an underlying myeloproliferative disorder in patients with Budd-Chiari syndrome or portal vein thrombosis
76. Natural history of paroxysmal nocturnal haemoglobinuria
77. Prevalence of the factor V leiden mutation in hepatic and portal vein thrombosis
78. Thromboembolism in patients with the 'lupus-like' circulating anticoagulant
79. The role of natural anticoagulant deficiencies and factor V Leiden in the development of idiopathic portal vein thrombosis
80. Inhibitor against factor V after liver transplantation
81. Acquired factor VIII inhibitor associated with chronic interferon-alpha therapy in a patient with haemophilia A
82. Acquired inhibitors to the coagulation factor XII associated with liver disease
83. Acquired thrombin inhibitor in a patient with liver cirrhosis
84. Current management of visceral artery aneurysms
85. Management of splenic artery aneurysms: The significance of portal and essential hypertension
86. Splenic artery aneurysms in liver transplant patients
87. The management of splenic artery aneurysms: Experience with 23 cases
88. The arterioportal fistula syndrome: Clinicopathologic features, diagnosis and therapy
89. Symptomatic hepatic disease in cystic fibrosis: Incidence, course, and outcome of portal systemic shunt
90. Natural history of liver disease in cystic fibrosis
91. Splenic 'regeneration' after partial splenectomy for Gauchers disease: Histological features
92. Differential effects of enzyme supplementation therapy on manifestations of type I Gaucher disease
93. Niemann-Pick disease type C; nodular splenomegaly
94. Late Niemann-Pick disease with neurovisceral storage: A classification problem
95. Idiopathic portal hypertension (hepatoportal sclerosis)
96. Changes in lymph vessels and portal veins in the portal tract of patients with idiopathic portal hypertension: A morphometric study
97. Structural characteristic of splenic sinuses in idiopathic portal hypertension
98. High rate of portal thrombosis after splenectomy in patients with esophageal varices and idiopathic portal hypertension
99. Hepatocyte transplantation in rats with decompensated cirrhosis